Dr. Tanya Dorff on latest progress with PARP inhibitors in mCRPC

Tanya Dorff, MD, discusses 3 pivotal trials—PROpel, MAGNITUDE, TALAPRO-2 trial—examining the potential of combining PARP inhibitors with androgen receptor–targeted agents in patients with metastatic castration-resistant prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.